32 Results for "

Dasitinib

" in MedChemExpress (MCE) Product Catalog:
Products (32)

32 Results for "Dasitinib" in MCE Product Catalog:

175
175 Publications Verification
Referencia número: HY-10181
No. CAS: 302962-49-8
Pureza:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier .
175
175 Publications Verification
Referencia número: HY-10181A
No. CAS: 854001-07-3
Pureza:  98.86%
Synonyms: BMS-354825 hydrochloride
Áreas de investigación:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
175
175 Publications Verification
Referencia número: HY-10181B
No. CAS: 863127-77-9
Pureza:  99.58%
Synonyms: BMS-354825 monohydrate
Áreas de investigación:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
6
6 Cited Publications
Referencia número: HY-10209
No. CAS: 790299-79-5
Pureza:  99.95%
Synonyms: AB1010
Áreas de investigación:  

Cancer

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
6
6 Cited Publications
Referencia número: HY-10209A
No. CAS: 1048007-93-7
Pureza:  99.51%
Synonyms: AB-1010 mesylate
Target:  

c-Kit PDGFR Src FGFR Apoptosis

Áreas de investigación:  

Cancer

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
1
1 Cited Publications
Referencia número: HY-10181S
No. CAS: 1132093-70-9
Pureza:  98.17%
Synonyms: BMS-354825-d8
Dasatinib-d8 (BMS-354825-d8) is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.
Referencia número: HY-131669
No. CAS: 910297-53-9
Pureza:  99.64%
Synonyms: Dasatinib carboxylic acid
Dasatinib metabolite M6 (Dasatinib carboxylic acid) is a circulating metabolite of Dasatinib (HY-10181). Dasatinib exhibits potent anti-tumor activity .
Referencia número: HY-107447
No. CAS: 910297-51-7
Pureza:  98.58%
Synonyms: N-Deshydroxyethyl BMS-354825
N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research .
Referencia número: HY-176461
No. CAS: 2468065-01-0
Target:  

Src Bcr-Abl

Áreas de investigación:  

Cancer

Pro-Dasatinib (compound 2j), an amino acid analog of Dasatinib (HY-10181), is a potent Src/Abl kinase inhibitor. Pro-Dasatinib has antiproliferative activity against K652 leukemia cancer cells with an IC50 of 0.21 nM.
Referencia número: HY-111857
No. CAS: 2112837-79-1
Pureza:  98.04%
Synonyms: BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4
Áreas de investigación:  

Cancer

Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
Referencia número: HY-133794
No. CAS: 910297-52-8
Pureza:  99.27%
Target:  

Drug Metabolite

Áreas de investigación:  

Cancer

Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor .
Referencia número: HY-10181R
No. CAS: 302962-49-8
Synonyms: BMS-354825 (Standard)
Áreas de investigación:  

Cancer

Dasatinib (Standard) is the analytical standard of Dasatinib. This product is intended for research and analytical applications. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
Referencia número: HY-176049
No. CAS: 3079237-53-6
Target:  

Drug Derivative

Áreas de investigación:  

Neurological Disease

Dasatinib derivative 1 (2e) effectively releases NO and increases the concentration of 3′,5′-cyclic guanosine monophosphate, as well as maintains senolytic activity. Dasatinib derivative 1 (2e) can be used in the research for chronic ocular hypertension (COHT) glaucoma .
Referencia número: HY-10181S1
No. CAS: 1160297-08-4
Synonyms: BMS-354825-d4
Dasatinib-d4 (BMS-354825-d4) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib also induces apoptosis and autophagy.
Referencia número: HY-176462
No. CAS: 2102305-55-3
Target:  

Drug Derivative

Áreas de investigación:  

Cancer

Gly-Dasatinib (compound I-7-1), an amino acid analog of Dasatinib (HY-10181), is a tyrosine kinase inhibitor. Gly-Dasatinib can be used for the study of cancer .
Referencia número: HY-156883
No. CAS: 1174416-41-1
Pureza:  98.08%
Target:  

Cytochrome P450

Áreas de investigación:  

Others

Dasatinib analog-1 (compound 5826) inhibits CYP3A4 viability with a Ki value of 5.4 μM. Dasatinib analog-1 blocks the formation of glutathione adducts .
Referencia número: HY-133794S
No. CAS: 1189988-36-0
Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor .
Referencia número: HY-W700620
No. CAS: 910297-58-4
Áreas de investigación:  

Inflammation/Immunology

Hydroxymethyl dasatinib (M24), a benzylhydroxy metabolite of Dasatinib (HY-10181), exhibits an IC50 of 46.7nM in K562 CML cells .
Referencia número: HY-41940
No. CAS: 302964-08-5
Target:  

Bcr-Abl

Áreas de investigación:  

Cancer

Dasatinib intermediate-1 is an intermediate in the synthesis of Dasatinib (HY-10181). Dasatinib Is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity .
Referencia número: HY-161687
No. CAS: 3049801-09-1
Target:  

Src

Áreas de investigación:  

Cancer

Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .